Shelton Capital Management’s Myriad Genetics MYGN Stock Holding History

Shelton Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,300	Closed	-$203K	–	855
2019 Q2	$203K	Buy	7,300 +7,049	+2,808%	+$199K	0.01%	767
2019 Q1	$7.57K	Sell	251 -7,318	-97%	-$223K	0.03%	477
2018 Q4	$220K	Buy	7,569 +555	+8%	+$20K	0.02%	654
2018 Q3	$323K	Buy	7,014 +438	+7%	+$19.5K	0.02%	549
2018 Q2	$246K	Buy	+6,576	New	+$222K	0.02%	685
2018 Q1	–	Sell	-6,576	Closed	-$226K	–	873
2017 Q4	$226K	Hold	6,576	–	–	0.01%	755
2017 Q3	$238K	Buy	+6,576	New	+$188K	0.02%	698

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Shelton Capital Management's MYGN Position: Q3 2019 in Review

Shelton Capital Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 7,300 shares — an estimated $203K sold.

Shelton Capital Management first reported a position in MYGN in Q3 2017 and held it in 7 quarters. The position peaked at $323K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Shelton Capital Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Shelton Capital Management sold 7,300 Myriad Genetics shares in Q3 2019, an estimated $203K.
Shelton Capital Management first reported a position in Myriad Genetics in Q3 2017 and held it in 7 quarters.
Shelton Capital Management's Myriad Genetics position peaked at $323K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Shelton Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.